CD19 and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T-cell immunotherapies are effective treatments that have drastically improved outcomes in patients with refractory B-cell malignancies and multiple myeloma [1–3]. Here, TNFRSF17 is linked to plasma cell myeloma.